Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shRNA-BPTF is a short hairpin RNA (shRNA) therapeutic candidate designed to silence the expression of the Bromodomain PHD finger transcription factor (BPTF). BPTF is a key component of the NURF (Nucleosome Remodeling Factor) complex and plays a significant role in chromatin remodeling. Research indicates that BPTF is overexpressed in melanoma and correlates with poor survival and resistance to BRAF inhibitors. By targeting BPTF mRNA for degradation via the RNA interference (RNAi) pathway, shRNA-BPTF aims to suppress tumor cell proliferation, reduce metastatic potential, and overcome drug resistance in BRAF-mutant melanomas.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shRNA-BPTF.